Evidence map›Paper›PMID 25270658›Full record

ArticleInflammation2015

Erythropoietin reduces acute lung injury and multiple organ failure/dysfunction associated to a scald-burn inflammatory injury in the rat.

Joao Rocha, Maria Eduardo-Figueira, Andreia Barateiro, Adelaide Fernandes, Dora Brites, Rui Pinto, Marisa Freitas, Eduarda Fernandes, Helder Mota-Filipe, Bruno Sepodes

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Inflammation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05857891 (The Effect of Erythropoietin on Alveolar Fluid Clearance in Patients With Acute Respiratory Distress Syndrome), which is not on this map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05857891 narecruitingnot on this mapstarted 2023, after this paper: background citation

The Effect of Erythropoietin on Alveolar Fluid Clearance in Patients With Acute Respiratory Distress Syndrome

TypeinterventionalSponsorSecond Affiliated Hospital of Wenzhou Medical UniversityRan2023 to 2027Enrolled40ConditionsAcute Respiratory Distress SyndromeArmsHuman erythropoietin injection, 0.9%NaCl
3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Role and Mechanism of Maresin-1 in Acute Lung Injury Induced by Trauma-Hemorrhagic Shock.Medical science monitor : international medical journal of experimental and clinical research · 2020
    Article
  8. Review
  9. Review
  10. Article
  11. Role of erythropoietin and its receptor in the development of endometriosis in ratsJournal of the Turkish German Gynecological Association · 2019
    Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Erythropoietin and diabetes mellitus.World journal of diabetes · 2015
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Joao RochaResearch Institute for Medicines (iMed.ULisboa), Avenida Prof. Gama Pinto, 1649-003, Lisbon, Portugal.
Maria Eduardo-Figueira
Andreia Barateiro
Adelaide Fernandes
Dora Brites
Rui Pinto
Marisa Freitas
Eduarda Fernandes
Helder Mota-Filipe
Bruno Sepodes
Rede de Química e Tecnologia · PTUniversidade do Porto · PTUniversity of Lisbon · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Erythropoietin (EPO) is an endogenous regulator of erythropoiesis and is given exogenously as a replacement therapy for selected red blood cell disorders. In the past years, EPO has been emerging as a multifunctional, cytoprotective cytokine with anti-apoptotic, anti-inflammatory, and immunomodulatory properties. We aimed to evaluate the cytoprotective effect of rhEPO (recombinant human EPO) treatment on a rat model of multiorgan dysfunction induced by thermal injury. rhEPO was administered at 1000 U/kg (i.v.) 5 min prior to induction of injury and significantly reduced multiorgan dysfunction markers (liver, kidney, lung, serum cytokine levels). In the lung, rhEPO reduced: histological signs of tissue injury, inflammatory/injury markers on the bronchoalveolar fluid, neutrophil chemotaxis/infiltration, GSK-3β activation, and apoptosis. Our study showed that erythropoietin has the potential to exhibit pleiotropic cytoprotective effects and that it might be an interesting pharmacological strategy in the modulation of acute lung injury, such as the one associated to severe burn.

Indexed as

Acute Lung InjuryAnimalsBurnsDose-Response Relationship, DrugEpoetin AlfaHumansInflammationMaleMultiple Organ FailureNeutrophilsRatsRats, WistarRecombinant ProteinsRespiratory BurstEpoetin AlfaRecombinant Proteins

Identifiers

PMID25270658
OpenAlexW2004717481

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.